Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x
Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous system, target engagement and tolerability.
